Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDO2 | P48775 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10250227 | 0.76 | PIK3CG (0.31) | — | |
| SCHEMBL14048895 | 0.74 | TDO2 (0.40) | TDO2MEN1KMT2APTPN11 | |
| SCHEMBL15834823 | 0.73 | TDO2 (0.37) | TDO2SMN1; SMN2 | |
| SCHEMBL2546878 | 0.69 | DYRK1A (0.48) | TDO2MEN1KMT2ASMN1; SMN2PTPN11 | |
| SCHEMBL21372012 | 0.69 | TDO2 (0.43) | TDO2PTPN11 | |
| SCHEMBL2627056 | 0.69 | MEN1 (0.54) | MEN1KMT2ASMN1; SMN2PTPN11 | |
| SCHEMBL15935280 | 0.69 | LMNA (0.31) | — | |
| SCHEMBL25450494 | 0.67 | MET (0.36) | KMT2A | |
| SCHEMBL12570327 | 0.66 | POLB (0.41) | — | |
| SCHEMBL21900465 | 0.65 | CYP1A2 (0.41) | MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10307413-B2 | Tetrahydro- and dihydro-isoquinoline PRMT5 inhibitors and uses thereof | Epizyme, Inc. (US) | 2019-06-04 | — | — | US | disclosed |
| US-20190083482-A1 | PRMT5 INHIBITORS AND USES THEREOF | Epizyme, Inc. (US) | 2019-03-21 | — | — | US | disclosed |
| US-20180162847-A1 | PRMT5 INHIBITORS CONTAINING A DIHYDRO- OR TETRAHYDROISOQUINOLINE AND USES THEREOF | Epizyme, Inc. (US) | 2018-06-14 | — | — | US | disclosed |
| US-20180162847-A1 | PRMT5 INHIBITORS CONTAINING A DIHYDRO- OR TETRAHYDROISOQUINOLINE AND USES THEREOF | Epizyme, Inc. (US) | 2018-06-14 | — | — | US | disclosed |
| US-20170334861-A1 | TETRAHYDRO- AND DIHYDRO-ISOQUINOLINE PRMT5 INHIBITORS AND USES THEREOF | Epizyme, Inc. (US) | 2017-11-23 | — | — | US | disclosed |
| US-9765068-B2 | PRMT5 inhibitors and uses thereof | Epizyme, Inc. (US) | 2017-09-19 | — | — | US | disclosed |
| US-9745291-B2 | PRMT5 inhibitors containing a dihydro- or tetrahydroisoquinoline and uses thereof | Epizyme, Inc. (US) | 2017-08-29 | — | — | US | disclosed |
| US-9745291-B2 | PRMT5 inhibitors containing a dihydro- or tetrahydroisoquinoline and uses thereof | Epizyme, Inc. (US) | 2017-08-29 | — | — | US | disclosed |
| US-20170210751-A1 | PRMT5 INHIBITORS AND USES THEREOF | Epizyme, Inc. (US) | 2017-07-27 | — | — | US | disclosed |
| US-20170210751-A1 | PRMT5 INHIBITORS AND USES THEREOF | Epizyme, Inc. (US) | 2017-07-27 | — | — | US | disclosed |
| US-20160368907-A1 | PRMT5 INHIBITORS AND USES THEREOF | Epizyme, Inc. (US) | 2016-12-22 | — | — | US | disclosed |
| US-20150361042-A1 | PRMT5 INHIBITORS AND USES THEREOF | Epizyme, Inc. (US) | 2015-12-17 | — | — | US | disclosed |
| US-20150344433-A1 | PRMT5 INHIBITORS CONTAINING A DIHYDRO- OR TETRAHYDROISOQUINOLINE AND USES THEREOF | Epizyme, Inc. (US) | 2015-12-03 | — | — | US | disclosed |
| US-20150191432-A1 | PRMT5 INHIBITORS AND USES THEREOF | Epizyme, Inc. (US) | 2015-07-09 | — | — | US | disclosed |
| US-8940726-B2 | PRMT5 inhibitors and uses thereof | Epizyme, Inc. (US) | 2015-01-27 | — | — | US | disclosed |
| US-20140221345-A1 | PRMT5 INHIBITORS AND USES THEREOF | Epizyme, Inc. (US) | 2014-08-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150191432-A1 | PRMT5 INHIBITORS AND USES THEREOF | PRMT5, PRMT1, PRMT6 | TDO2 3751/4885MEN1 1329/4885KMT2A 58/4885 |
| US-20140221345-A1 | PRMT5 INHIBITORS AND USES THEREOF | PRMT5, PRMT1, PRMT6 | TDO2 3751/4885MEN1 1329/4885KMT2A 58/4885 |
| US-20150344433-A1 | PRMT5 INHIBITORS CONTAINING A DIHYDRO- OR TETRAHYDROISOQUINOLINE AND USES THEREOF | PRMT5, PRMT1, PRMT3 | TDO2 3069/4885MEN1 1238/4885KMT2A 35/4885 |
| US-10307413-B2 | Tetrahydro- and dihydro-isoquinoline PRMT5 inhibitors and uses thereof | PRMT5, PRMT1, PRMT3 | TDO2 2634/4885MEN1 1665/4885KMT2A 48/4885 |
| US-20190083482-A1 | PRMT5 INHIBITORS AND USES THEREOF | PRMT5, PRMT1, PRMT6 | TDO2 3751/4885MEN1 1329/4885KMT2A 58/4885 |
| US-20160368907-A1 | PRMT5 INHIBITORS AND USES THEREOF | PRMT5, PRMT1, PRMT6 | TDO2 3751/4885MEN1 1329/4885KMT2A 58/4885 |
| US-20150361042-A1 | PRMT5 INHIBITORS AND USES THEREOF | PRMT5, PRMT1, PRMT6 | TDO2 3804/4885MEN1 1416/4885KMT2A 37/4885 |
| US-20170334861-A1 | TETRAHYDRO- AND DIHYDRO-ISOQUINOLINE PRMT5 INHIBITORS AND USES THEREOF | PRMT5, PRMT1, PRMT3 | TDO2 2634/4885MEN1 1665/4885KMT2A 48/4885 |
| US-20170210751-A1 | PRMT5 INHIBITORS AND USES THEREOF | PRMT5, PRMT1, PRMT6 | TDO2 2466/4885MEN1 628/4885KMT2A 64/4885 |
| US-20180162847-A1 | PRMT5 INHIBITORS CONTAINING A DIHYDRO- OR TETRAHYDROISOQUINOLINE AND USES THEREOF | PRMT5, PRMT1, PRMT3 | TDO2 3069/4885MEN1 1238/4885KMT2A 35/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.